3 New Strong Buy Ratings from Top-Rated Analysts: 05/06/2025

Happy Tuesday! Let’s get the week going strong with some investing inspo from WallStreetZen’s Strong Buy Stocks from Top Wall Street Analysts screener:

• Adeia (ADEA) has high-profile clients — and high potential, according to experts
• Twilio (TWLO) is getting a lot of attention — here’s why
• The “Ozempic Effect” isn’t fading — find out why analysts are still keen on Eli Lilly (LLY)

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

1. Adeia (NASDAQ: ADEA)

Adeia is quite an interesting case. The company operates in the media, entertainment, and semiconductor industries. If you’re wondering how it can wear so many disparate hats, the answer is this — this company develops, and then monetizes intellectual property, which is then licensed to major players in these industries. Some of its most notable clients include Amazon, Samsung, and LG. Moreover, the company’s valuation — as well as its growth prospects, make it quite an attractive pick.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $12.61 — get current quote > 

Max 1-year forecast: $20.00 

Why we’re watching:

• Adeia stock currently has 3 analyst ratings — 2 Strong Buys and 1 Buy. See the ratings 
• Hamed Khorsand of BWS Financial (a top 10% rated analyst) recently doubled down on a Buy rating, and kept an $18.00 price target on ADEA shares.
• A similar outlook is shared by Rosenblatt’s Kevin Cassidy (a top 12% rated analyst), who maintains a Strong Buy rating on Adeia stock with a $20 price target.
• ADEA is currently the 2nd highest-rated stock in the App industry, which has an Industry Rating of B.
• Adeia stock has an overall Zen Rating of A, and ranks in the top 1% of equities once all 7 Component Grade ratings are taken into account.
• Speaking of Component Grade ratings, Financials are ADEA’s strongest suit, as it ranks in the top 1% in this regard. > Here’s why “Boring Financials” are so crucial for stocks
• However, the stock also ranks quite highly in terms of Value and Growth — where it ranks in the 91st and 89th percentile. (See all 7 Zen Component Grades here >)

2. Twilio (NYSE: TWLO)

Twilio works magic behind the scenes. The company’s cloud-based platform is what allows numerous companies to so seamlessly integrate voice, messaging, video, and authentication features into their own platforms. While we might not have heard of it before, Wall Street has obviously been paying attention — you’ll be surprised to learn just how much attention TWLO stock has attracted.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $100.11 — get current quote > 

Max 1-year forecast: $170.00 

Why we’re watching:

• Twilio stock enjoys extensive analyst coverage — and the average outlook is quite bullish. TWLO currently has 7 Strong Buy ratings, 10 Buy ratings, 3 Hold ratings, and a single Sell rating. See the ratings 
• The average price target for TWLO stands at $137.57 — a figure that implies a 37.42% upside compared to current prices.
• Piper Sandler researcher James Fish (a top 17% rated analyst) reiterated a Strong Buy rating on Twilio shares on May 2, and upped his 12-month price forecast from $106 to $121. 
• Fish attributed their price target hike and the 10% post-print bump in the stock price to "results above buyside expectations, which showed further acceleration complemented by free cash flow leverage and a slightly better Q2 guide from management.".
• At present, TWLO is the 4th highest-rated stock in the Internet Content & Information industry, which has an Industry Rating of B. 
• Twilio stock carries an overall Zen Rating of A, and ranks in the 96th percentile of all the stocks that we track.
• TWLO ranks in the 99th percentile in terms of its Growth Component Grade rating, and the top 6% of stocks in terms of Sentiment (See all 7 Zen Component Grades here >)

3. Eli Lilly (NYSE: LLY)

Weight loss drugs put pharma stocks back in the spotlight — Mounjaro and tirzepatide did it for Eli Lilly. In 2024, the business marked a 32% increase in full-year revenue — exceeding its own guidance by a staggering $4 billion. Those weight loss drugs have only one major flaw — at this point, they’re all injectable. However, Eli Lilly recently released phase 3 trial data for Orforglipron — an oral weight-loss drug, which demonstrated both similar results and safety when compared to injectables.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $823.62 — get current quote > 

Max 1-year forecast: $1,190.00 

Why we’re watching:

• LLY currently has 12 analyst ratings — 10 of which are Strong Buys, rounded out by 1 Buy rating and 1 Sell rating. See the ratings
• UBS researcher Trung Huynh (a top 13% rated analyst) recently reissued a Strong Buy rating on Eli Lilly shares but cut his price forecast from $1,100 to $1,050.
• The revision came after the company’s Q1 2025 earnings call — given the strong performance of the GLP franchise, Huynh argued that the current selloff, which has seen LLY stock price slide by 6.89% in a week, is excessive.
• Eli Lilly stock has an overall Zen Rating of B, and ranks in the top 12% of stocks overall. Stocks with this distinction have historically provided an average annual return of 19.88% — and the average 12-month price forecast for LLY currently implies a 21.47% upside.
• Growth is the drug company’s most notable strength. The enduring demand for weight loss medication has given LLY a spot in the top 8% of equities in this regard. (Here’s the right way to track Growth potential…)

However, Value and Financials are not far behind, as Eli Lilly ranks in the 80th and 81st percentile, respectively, in those categories. (See all 7 Zen Component Grades here >)

What to Do Next?

• 200 Stocks to Sell Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.